
Samuel Hume/oncology.ox.ac.uk
Apr 20, 2025, 19:13
Samuel Hume on FDA approvals Q1 2025: New antibiotics, ADCs for breast cancer and first pain medication targeting NaV1.8 sodium channel
Samuel Hume, Fellow at The Foulkes Foundation and pursuing PhD in the University of Oxford’s Department of Oncology, shared a post on X:
“What new drugs have been FDA-approved so far in 2025?
Among them is an antibiotic with a unique mode-of-action, a new antibody-drug conjugate for breast cancer, and the first pain medication that’s selective for the NaV1.8 sodium channel.”
FDA new drug approvals in Q1 2025
Author: Paul Verdin
Learn more about new drug developments in oncology on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 19:05
Apr 20, 2025, 17:33